Clinical Trials Logo

Filter by:
NCT ID: NCT05197075 Completed - Clinical trials for Human Immunodeficiency Virus (HIV)

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Start date: August 3, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the ability to swallow the Darunavir/Cobicistat (DRV/COBI) fixed dosed combination (FDC) tablet dispersed in water.

NCT ID: NCT05195255 Completed - Healthy Clinical Trials

Metabolic Response of Intestinal Microbiota to Guar Gum Consumption

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Some components of the diet are not absorbed in the small intestine and pass into the colon, where they may be fermented by the microbiota, releasing gas. A series of recent studies suggest that some non-absorbable, fermentable meal products (prebiotics) serve as substrate to colonic bacteria and change their composition, thereby producing beneficial effects to the host. These products are fermented by bacteria and at initial intake increase gas production; however, after 7-10 days administration some prebiotics induce an adaptation of intestinal microbiota towards more efficient metabolic pathways with less gas production. Hence, intestinal gas production may serve as an index of microbiota metabolic activity. Gas production may induce gas-related symptoms, such as flatulence, abdominal bloating and distention, and the symptoms improve when the microbiota adapts to the prebiotic and gas production declines. Guar gum is classified as a fiber, but it remains uncertain whether and to what extent it is fermented by colonic microbiota and whether it has prebiotic properties. Aim: to determine the metabolic reaction of intestinal microbiota in response to guar gum consumption, specifically, the extent of initial fermentation and subsequent adaptation.Design: Single-centre, single arm, open label, proof-of-concept study testing the effect of guar gum on microbiota metabolism and adaptation in healthy subjects Intervention: guar gum (8 g/d) will be administered for 18 days. Outcomes: during 4 days immediately before, at the beginning and at the end of the administration phase participants will be put on a standard diet and the following outcomes will be measured: a) number of gas evacuations during daytime for 2 days by means of an event marker; b) perception of digestive sensations by daily scales; c) microbiota composition by fecal analysis; d) metabolites in urine.

NCT ID: NCT05195099 Completed - COVID-19 Pandemic Clinical Trials

Respiratory Physiotherapy and Neurorehabilitation in Patients With Post-covid19 Sequelae.

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

The objectives are to reduce dyspnoea, increase exertional capacity, increase vital capacity and respiratory muscle strength. vital capacity and respiratory muscle strength. In addition to increasing the sensibility of smell and taste, observing if there is a relationship between the decrease of these senses with the senses with appetite and whether appetite has normalised in post-SARS-CoV-2 patients. It is a randomised and blinded experimental study with a control group where the sample recruited will be 30 patients, with a range of of 30 patients, with an age range of 19-42 years, where they carried out an assessment of spirometry, modified Borg dyspnoea scales and modified Medical Research Council (MMRC), Singapure (MMRC), Singapore Smell and Taste Questionnaire (SSTQ) and weekly smell and taste questionnaire. taste questionnaire.

NCT ID: NCT05194306 Completed - Clinical trials for Ischemic Reperfusion Injury

PERTRIAL - Perla® Preservation Solution

Start date: December 11, 2021
Phase: N/A
Study type: Interventional

Perla® is a Cold Preservation Solution, with purpose to wash out, preserve during transport liver and kidney grafts in optimal conditions from the donor to the recipient. The purpose of the PERTRIAL clinical investigation is to demonstrate the Performance and Safety of Perla® Cold Preservation solution.

NCT ID: NCT05192200 Completed - Dermatomyositis Clinical Trials

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

Start date: December 20, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.

NCT ID: NCT05190900 Completed - Rehabilitation Clinical Trials

Changes in Stabilometry After Neural Mobilisation in Foot

Start date: August 29, 2022
Phase: N/A
Study type: Interventional

Investigation will consist of measuring before and after applying nerve mobilization exercise. Measurements will be made on the same day without the need to go at another time. In this study, participants will be asked to stand on a pressure platform several times in a relaxed manner and with eyes open and closed before and after a neuromeningeal mobilization technique indicated for the treatment of pain in your feet. Measurements or tests to be carried out are totally innocuous and do not carry any risk to your health and integrity. Participants will have to remain barefoot for a maximum of 30 seconds, a total of 8 times on a pressure platform

NCT ID: NCT05190224 Completed - Rehabilitation Clinical Trials

Changes in Plantar Preassures and Ankle Range of Motion After the Technique of Neuromeningeal Mobilization

Start date: January 27, 2022
Phase: N/A
Study type: Interventional

Neuromeningeal mobilization or neurodynamics is a movement-based technique whose purpose is to restore peri- and intraneural homeostasis (1). It is based on principle that nerves have to lengthen and shorten to maintain normal muscle tension and range of motion (1) This technique has been shown to be effective in recovering tissue mobility (2), reducing pain in low back pain (3) and neck pain (1) and pain intensity in the elderly, and increasing joint range of motion and muscle flexibility (4 ) Regarding balance, sciatic nerve sliding has been shown to immediately improve balance to one leg ( dinamic balance) after application in a comparative study before and after (4,5) No study has been realised in for the Posterior Tibial, Deep Peroneal, Medial Dorsocutaneous and Lateral Nerves, and no study has verificated standing balance and range of motion in ankle joint

NCT ID: NCT05190029 Completed - Clinical trials for Child Development Disorder

Craniosacral Test and Primitive Reflexes in Infant Neurodevelopment

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Question(s): Can active primitive reflexes (APR) and cranial blocks (CB) in healthy children interfere with neurological balance causing psycho-behavioral and cognitive dysfunctions? Design: Cross-sectional and descriptive study analyzing perinatal, neurobehavioral and physiotherapeutic parameters. Participants: School population of both genders (n=120) divided in two groups: 3-6 years old (n=60) and 6-8 years old (n=60). Intervention: Systematic evaluation of the children based on a parent survey, assessment by teachers and physiotherapeutic exploration. Outcome measures: Perinatal (surveyed parents) and neurobehavioral problems (assessed by teachers) were related to the presence of RPA and BC (analyzed by physiotherapeutic exploration). Key words: primitive reflexes, craniosacral disfunctions, neurodevelopment, childhood, early diagnosis, screening.

NCT ID: NCT05187143 Completed - Clinical trials for Implant Site Reaction

Results of a New Fully Tapered Implant at One Year

Start date: June 1, 2019
Phase:
Study type: Observational

Objective: The aim of this prospective observational clinical study is to evaluate the bone level changes in a new implant design, fully tapered and platform switching with the one-time one-abutment protocol after one year of loading. Material and methods: Thirty patients received 1 or 2 implants (6, 8 and 10 mm in length, 3.5, 3.75 or 4.5 mm diameter and bone level design) to replace a single or multiple gap. Radiographic, clinical, esthetic and survival success rate were evaluated after one year of loading. Results: At 12 months post final loading, there were no peri-implant bone loss in any of the cases. Mean marginal crestal bone loss between surgery and crown placement was 0.19 ± 0.17 (p <0.0001). Between surgery and 12 months of follow-up, the mean marginal crestal bone loss was 0.25 ± 0.24 (p <0.0001). There were a SSD between 1 year follow-up and crown placement in PI in the mesial (0.33 ± 0.54 p= 0.003) and distal aspect (0.5 ± 0.73 p= 0.001). The PPD was SSD deeper at 1 year follow-up than at crown placement only in the mesial and distal probing (averaged depth=0.75 and p<0.0005). No statistically significant differences were found for any of the other clinical and est

NCT ID: NCT05186818 Completed - Clinical trials for Obstructive Hypertrophic Cardiomyopathy (oHCM)

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM)

SEQUOIA-HCM
Start date: February 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction